COMMENTARY: Review: Ribavirin is not better than placebo in chronic hepatitis C infection

Chen, Wendong; Krahn, Murray
September 2006
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p47
Academic Journal
The article presents comments on studies examining whether ribavirin is better than placebo in chronic hepatitis C infection. It was seen that ribavirin monotherapy was not associated with significant benefit in terms of sustained viral response. It was not related to liver-related morbidity, or all-cause mortality also. Review of the studies showed that approximately 19% of patients treated with ribavirin might develop anemia. However, withdrawals may be experienced due to adverse effects.


Related Articles

  • Review: Ribavirin is not better than placebo in chronic hepatitis C infection.  // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p47 

    The article focuses on studies which examine whether ribavirin monotherapy is more effective than placebo in patients with chronic hepatitis C infection, or whether no intervention is required. Assessment of individual studies was based on randomization, allocation concealment, and blinding. It...

  • A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure. Snoeck, E.; Chanu, P.; Lavielle, M.; Jacqmin, P.; Jonsson, E. N.; Jorga, K.; Goggin, T.; Grippo, J.; Jumbe, N. L.; Frey, N. // Clinical Pharmacology & Therapeutics;Jun2010, Vol. 87 Issue 6, p706 

    We propose a model that characterizes and links the complexity and diversity of clinically observed hepatitis C viral kinetics to sustained virologic response (SVR)—the primary clinical end point of hepatitis C treatment, defined as an undetectable viral load at 24 weeks after completion...

  • Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Oze, Tsugiko; Hiramatsu, Naoki; Kurashige, Nao; Tsuda, Natsuko; Yakushijin, Takayuki; Kanto, Tatsuya; Takehara, Tetsuo; Kasahara, Akinori; Kato, Michio; Yoshihara, Harumasa; Katayama, Kazuhiro; Kubota, Shinji; Hijioka, Taizo; Ishibashi, Kazunobu; Oshita, Masahide; Hagiwara, Hideki; Haruna, Yoshimichi; Mita, Eiji; Tamura, Shinji; Hayashi, Norio // Journal of Gastroenterology;Sep2006, Vol. 41 Issue 9, p862 

    The aim of this study was to examine the factors correlated with the progression of ribavirin-induced hemolytic anemia in patients with chronic hepatitis C treated by interferon and ribavirin combination therapy. This study was conducted on 505 patients by the Osaka Liver Disease Study Group. A...

  • Evidence of Recombination in Intrapatient Populations of Hepatitis C Virus. Sentandreu, Vicente; Jiménez-Hernández, Nuria; Torres-Puente, Manuela; Bracho, María Alma; Valero, Ana; Gosalbes, María José; Ortega, Enrique; Moya, Andrés; González-Candelas, Fernando // PLoS ONE;2008, Vol. 3 Issue 9, p1 

    Hepatitis C virus (HCV) is a major cause of liver disease worldwide and a potential cause of substantial morbidity and mortality in the future. HCV is characterized by a high level of genetic heterogeneity. Although homologous recombination has been demonstrated in many members of the family...

  • Sustained Virological Response to Interferon Plus Ribavirin Reduces Non–Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus. Berenguer, Juan; Rodríguez, Elena; Miralles, Pilar; Von Wichmann, Miguel A.; López-Aldeguer, José; Mallolas, Josep; Galindo, María J.; Van Den Eynde, Eva; Téllez, María J.; Quereda, Carmen; Jou, Antoni; Sanz, José; Barros, Carlos; Santos, Ignacio; Pulido, Federico; Guardiola, Josep M.; Ortega, Enrique; Rubio, Rafael; Jusdado, Juan J.; Montes, María L. // Clinical Infectious Diseases;Sep2012, Vol. 55 Issue 5, p728 

    We observed that eradication of hepatitis C virus in patients coinfected with human immunodeficiency virus (HIV) was associated not only with a reduction in liver-related complications and mortality but also with a reduction in the progression of HIV infection and mortality not related to liver...

  • Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. Macías, Juan; Del Valle, José; Rivero, Antonio; Mira, José A.; Camacho, Ángela; Merchante, Nicolás; Pérez-Camacho, Inés; Neukam, Karin; Rivero-Juárez, Antonio; Mata, Rosario; Torre-Cisneros, Julián; Pineda, Juan A. // Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2204 

    Objectives: To evaluate the changes in liver stiffness measurement (LSM) in patients infected by hepatitis C virus (HCV) under pegylated interferon (Peg-IFN) plus ribavirin therapy.

  • Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection. Erqou, Sebhat; Mohanty, Arpan; Kasi, Pashtoon Murtaza; Butt, Adeel A. // ISRN Otolaryngology;2014, p1 

    Background. Understanding the predictors of mortality in individuals with human immunodeficiency virus and hepatitis C virus (HIV/HCV) coinfection can be useful in management of these patients. Methods. We used the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) for these...

  • Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. Kobayashi, Tomoe; Hige, Shuhei; Terashita, Katsumi; Nakai, Masato; Horimoto, Hiromasa; Sho, Takuya; Nakanishi, Mitsuru; Ogawa, Koji; Chuma, Makoto; Sakamoto, Naoya; Asaka, Masahiro // Journal of Gastroenterology;Nov2012, Vol. 47 Issue 11, p1228 

    Background: An inosine triphosphatase ( ITPA) single-nucleotide polymorphism (SNP) is associated with anemia induced by pegylated interferon and ribavirin (RBV) combination therapy in patients with chronic hepatitis C (CHC). However, there are very few reports on the hematological effects of RBV...

  • Treatment of chronic hepatitis C. Davis, Gary L // BMJ: British Medical Journal (International Edition);11/17/2001, Vol. 323 Issue 7322, p1141 

    Editorial. Focuses on treatment of chronic infection with hepatitis C virus. Reduction in the number of new hepatitis C infections as a result of improved blood screening and changes in injected drug use; Risk of death from chronic infections which lead to chronic liver disease; Initial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics